---
provider: asta
model: Asta Scientific Corpus Retrieval
cached: false
start_time: '2026-05-27T00:15:35.203246'
end_time: '2026-05-27T00:15:41.555357'
duration_seconds: 6.35
template_file: templates/hypothesis_deep_research.md
template_variables:
  disease_name: COVID-19
  category: ''
  hypothesis_group_id: endotheliopathy_centred_pathophysiology_model
  hypothesis_label: Endotheliopathy-Centred Pathophysiology Model
  hypothesis_status: EMERGING
  hypothesis_yaml: "hypothesis_group_id: endotheliopathy_centred_pathophysiology_model\n\
    hypothesis_label: Endotheliopathy-Centred Pathophysiology Model\nstatus: EMERGING\n\
    description: 'Severe COVID-19 is increasingly framed as an endotheliopathy in\
    \ which SARS-CoV-2-driven\n  endothelial activation, thrombo-inflammation, and\
    \ parenchymal injury \u2014 rather than direct cytopathic\n  respiratory infection\
    \ alone \u2014 define the lethal disease phenotype. Under the interactome- rebalancing\n\
    \  framing, the lung endothelial interactome shifts toward a pro-thrombotic, hyper-inflammatory\
    \ state that\n  sits downstream of viral entry but upstream of multi-organ dysfunction.\
    \ This hypothesis is parallel\n  to (not subsumed by) the macrodomain countermeasure\
    \ model: Mac1 explains immune evasion at the cellular\n  level, while endotheliopathy\
    \ explains organ-scale pathology and many of the distinctive thrombotic complications.'\n\
    evidence:\n- reference: PMID:33965003\n  supports: SUPPORT\n  evidence_source:\
    \ OTHER\n  snippet: evidence for many distinctive mechanistic features indicates\
    \ that COVID-19 constitutes a new\n    disease entity, with emerging data suggesting\
    \ involvement of an endotheliopathy-centred pathophysiology\n  explanation: Osuchowski\
    \ et al. Lancet Respir Med review positions endotheliopathy as the unifying pathophysiological\n\
    \    framework for severe COVID-19, distinct from purely respiratory cytopathic\
    \ injury.\n- reference: PMID:33965003\n  supports: SUPPORT\n  evidence_source:\
    \ OTHER\n  snippet: Such complex manifestations suggest that SARS-CoV-2 dysregulates\
    \ the host response, triggering\n    wide-ranging immuno-inflammatory, thrombotic,\
    \ and parenchymal derangements.\n  explanation: Directly supports the multi-system,\
    \ interactome-rebalancing framing of severe COVID-19\n    as a host-response dysregulation\
    \ rather than direct viral cytopathology alone."
provider_config:
  timeout: null
  max_retries: 3
  parameters:
    allowed_domains: []
    query_char_limit: 500
    paper_limit: 50
    snippet_limit: 20
    snippet_paper_limit: 50
    restrict_snippets_to_papers: false
    paper_fields: title,abstract,authors,year,url,venue,journal,tldr,publicationDate,citationCount,influentialCitationCount,externalIds
    publication_date_range: ''
    venues: ''
    inserted_before: ''
citation_count: 17
---

## Question

# Mechanistic Hypothesis Search

You are evaluating a specific disease mechanism hypothesis for the Disorder
Mechanisms Knowledge Base. This is not a general disease overview. Use the
hypothesis YAML below as the seed claim, then search for evidence that supports,
refutes, qualifies, or competes with this hypothesis.

## Target Disease
- **Disease Name:** COVID-19
- **Category:**

## Target Hypothesis
- **Hypothesis ID:** endotheliopathy_centred_pathophysiology_model
- **Hypothesis Label:** Endotheliopathy-Centred Pathophysiology Model
- **Status in KB:** EMERGING

## Seed Hypothesis YAML

```yaml
hypothesis_group_id: endotheliopathy_centred_pathophysiology_model
hypothesis_label: Endotheliopathy-Centred Pathophysiology Model
status: EMERGING
description: 'Severe COVID-19 is increasingly framed as an endotheliopathy in which SARS-CoV-2-driven
  endothelial activation, thrombo-inflammation, and parenchymal injury — rather than direct cytopathic
  respiratory infection alone — define the lethal disease phenotype. Under the interactome- rebalancing
  framing, the lung endothelial interactome shifts toward a pro-thrombotic, hyper-inflammatory state that
  sits downstream of viral entry but upstream of multi-organ dysfunction. This hypothesis is parallel
  to (not subsumed by) the macrodomain countermeasure model: Mac1 explains immune evasion at the cellular
  level, while endotheliopathy explains organ-scale pathology and many of the distinctive thrombotic complications.'
evidence:
- reference: PMID:33965003
  supports: SUPPORT
  evidence_source: OTHER
  snippet: evidence for many distinctive mechanistic features indicates that COVID-19 constitutes a new
    disease entity, with emerging data suggesting involvement of an endotheliopathy-centred pathophysiology
  explanation: Osuchowski et al. Lancet Respir Med review positions endotheliopathy as the unifying pathophysiological
    framework for severe COVID-19, distinct from purely respiratory cytopathic injury.
- reference: PMID:33965003
  supports: SUPPORT
  evidence_source: OTHER
  snippet: Such complex manifestations suggest that SARS-CoV-2 dysregulates the host response, triggering
    wide-ranging immuno-inflammatory, thrombotic, and parenchymal derangements.
  explanation: Directly supports the multi-system, interactome-rebalancing framing of severe COVID-19
    as a host-response dysregulation rather than direct viral cytopathology alone.
```

## Research Objective

Build a focused hypothesis-search report that answers:

1. What is the strongest direct evidence for this hypothesis?
2. What evidence argues against it, fails to reproduce it, or limits its scope?
3. Which claims are established, emerging, speculative, or contradicted?
4. Which patient subtypes, stages, tissues, cell types, molecular pathways, or
   biomarkers does the hypothesis best explain?
5. Which alternative or competing mechanistic hypotheses explain the same disease
   features better or more parsimoniously?
6. What are the explicit knowledge gaps: missing causal steps, unconfirmed edges,
   contradictory evidence, unknown source-to-target links, or source/data absences?
7. What experiments, cohorts, assays, datasets, or trials would most directly
   distinguish this hypothesis from alternatives?

Use primary literature whenever possible. Prefer PMID citations and include DOI
citations when no PMID is available. Treat reviews as orientation unless they
contain directly relevant synthesized evidence that should be clearly labeled as
review-level support.

## Required Output

### Executive Judgment

Give a concise verdict on the hypothesis as of the current literature:
supported, partially supported, unresolved, weakly supported, or refuted. Explain
the reasoning and the most important caveats.

### Evidence Matrix

Create a table with one row per important evidence item:

- Citation (PMID preferred)
- Evidence type (human clinical, model organism, in vitro, computational, review)
- Supports / refutes / qualifies / competing
- Mechanistic claim tested
- Key finding
- Disease subtype or context
- Confidence and limitations

### Mechanistic Causal Chain

Describe the causal chain implied by the hypothesis from upstream trigger to
clinical manifestation. Identify where the literature is strong, where the links
are inferred, and where there are missing causal steps.

### Knowledge Gaps

Identify explicit known unknowns surfaced by the search. Treat absence of
evidence as a curation-relevant finding only when the search actually checked for
it. Include:

- Unknown or weakly supported causal steps in the hypothesis
- Unconfirmed causal graph edges that need direct perturbation or longitudinal
  evidence
- Conflicting evidence, failed replications, or incompatible subtype-specific
  findings
- Unknown mechanism of action for relevant treatments, biomarkers, or
  interventions tied to this hypothesis
- Source-level or dataset-level absences, such as no relevant GenCC, ClinGen,
  trial, omics, or cohort evidence found as of the search date

For each gap, state the scope, why it matters, what was checked, and what
evidence or experiment would resolve it.

### Alternative Models

List competing or complementary hypotheses. For each, explain whether it is an
alternative to the seed hypothesis, a downstream consequence, an upstream cause,
or a parallel mechanism.

### Discriminating Tests

Recommend concrete studies or assays that would most efficiently test this
hypothesis against alternatives. Include patient stratification, biomarkers,
sample type, model system, perturbation, and expected result where applicable.

### Curation Leads

Provide candidate updates for the KB, but label these as leads requiring curator
verification. Include:

- candidate evidence references and exact abstract snippets to verify
- candidate pathophysiology nodes or edges
- candidate ontology terms for cell types and biological processes
- candidate subtype restrictions or status changes
- candidate `knowledge_gaps` or discussion prompts for unresolved causal claims,
  conflicting evidence, or explicit source/data absences

If the provider supports artifacts, produce artifact-friendly outputs such as an
evidence matrix, mechanistic diagram, knowledge-gap table, or comparison table.
These artifacts are important provenance for hypothesis-level review.


## Output

# Asta Literature Retrieval: Mechanistic Hypothesis Search You are evaluating a specific disease mechanism hypothesis for the Disorder Mechanisms...

This report is retrieval-only and is generated directly from Asta results.

- Papers retrieved: 17
- Snippets retrieved: 20

## Relevant Papers

### [1] Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence
- Authors: C. Sardu, J. Gambardella, M. Morelli, Xujun Wang, R. Marfella et al.
- Year: 2020
- Venue: Journal of Clinical Medicine
- URL: https://www.semanticscholar.org/paper/4d651bbb3c8a3c9a309e06a998787416f96ee36d
- DOI: 10.3390/jcm9051417
- PMID: 32403217
- PMCID: 7290769
- Citations: 472
- Influential citations: 16
- Summary: A systematic and comprehensive evaluation of both clinical and preclinical evidence supporting the hypothesis that the endothelium is a key target organ in COVID-19 is reported, providing a mechanistic rationale behind its systemic manifestations.
- Evidence snippets:
  - Snippet 1 (score: 0.658)
    > The symptoms most commonly reported by patients affected by coronavirus disease (COVID-19) include cough, fever, and shortness of breath. However, other major events usually observed in COVID-19 patients (e.g., high blood pressure, arterial and venous thromboembolism, kidney disease, neurologic disorders, and diabetes mellitus) indicate that the virus is targeting the endothelium, one of the largest organs in the human body. Herein, we report a systematic and comprehensive evaluation of both clinical and preclinical evidence supporting the hypothesis that the endothelium is a key target organ in COVID-19, providing a mechanistic rationale behind its systemic manifestations.

### [2] Whole patient knowledge modeling of COVID-19 symptomatology reveals common molecular mechanisms
- Authors: S. Brock, David B Jackson, Theodoros G. Soldatos, K. Hornischer, Anne Schäfer et al.
- Year: 2023
- Venue: Frontiers in Molecular Medicine
- URL: https://www.semanticscholar.org/paper/c4cb8ce50e078b71d83a74b18eef01fac0748cbe
- DOI: 10.3389/fmmed.2022.1035290
- PMID: 39086962
- PMCID: 11285600
- Citations: 3
- Summary: This work followed an iterative, expert-driven process to compile data published prior to and during the early stages of the pandemic into a comprehensive COVID-19 knowledge model, suggesting the importance of whole patient knowledge frameworks in hypothesis generation and testing.
- Evidence snippets:
  - Snippet 1 (score: 0.600)
    > Infection with SARS-CoV-2 coronavirus causes systemic, multi-faceted COVID-19 disease. However, knowledge connecting its intricate clinical manifestations with molecular mechanisms remains fragmented. Deciphering the molecular basis of COVID-19 at the whole-patient level is paramount to the development of effective therapeutic approaches. With this goal in mind, we followed an iterative, expert-driven process to compile data published prior to and during the early stages of the pandemic into a comprehensive COVID-19 knowledge model. Recent updates to this model have also validated multiple earlier predictions, suggesting the importance of such knowledge frameworks in hypothesis generation and testing. Overall, our findings suggest that SARS-CoV-2 perturbs several specific mechanisms, unleashing a pathogenesis spectrum, ranging from "a perfect storm" triggered by acute hyper-inflammation, to accelerated aging in protracted "long COVID-19" syndromes. In this work, we shortly report on these findings that we share with the community via 1) a synopsis of key evidence associating COVID-19 symptoms and plausible mechanisms, with details presented within 2) the accompanying "COVID-19 Explorer" webserver, developed specifically for this purpose (found at https://covid19. molecularhealth.com). We anticipate that our model will continue to facilitate clinico-molecular insights across organ systems together with hypothesis generation for the testing of potential repurposing drug candidates, new pharmacological targets and clinically relevant biomarkers. Our work suggests that whole patient knowledge models of human disease can potentially expedite the development of new therapeutic strategies and support evidence-driven clinical hypothesis generation and decision making.
  - Snippet 2 (score: 0.540)
    > computer-augmented modeling approach, guided by disease modeling experts that allowed us to build a comprehensive digital model during the early phases of the pandemic (Brock et al., 2022).
    > In this work, we explore the utility and importance of the holistic patient-level knowledge model within the COVID-19 Explorer resource and examine its key features, particularly surrounding the molecular underpinnings of COVID-19 symptomatology. Characteristically, the model suggests that the multitude and complexity of observed, and seemingly disparate COVID-19 clinical phenotypes may be linked to the pleiotropic activity of eight core molecular mechanisms involved in the host response. Moreover, the model revealed functionally connected mechanisms across multiple organ systems and identified novel hypotheses for both viral dependent and independent disease mechanisms. Here, we discuss these molecular perspectives in detail, including the content of the causative pathogenic mechanisms underlying COVID-19 phenotypes, real world confirmatory observations, and examples that demonstrate some of the key analytical utilities (e.g., risk factors). Finally, we focus on the detection of potentially new (or unobvious) clinico-molecular insights across organsystems and on the identification of potential pharmacologic targets against COVID-19 (Brock et al., 2022).
    > Our results show that structuring emergent molecular knowledge via a pan-symptomatic disease format, helped develop a comprehensive whole patient COVID-19 knowledge model that could expedite evidence-driven hypothesis generation and the discovery of novel clinico-molecular insights. Inspired by the effectiveness of this strategy, we propose that whole-patient knowledge modeling of systemic symptomatology for any disease, as opposed to traditional pathway-specific modeling, may provide important advantages in tackling current unmet medical needs and future health emergencies. Importantly, the whole-patient knowledge model is provided to the community in the form of both an open-source web-sever (found at https://covid19. molecularhealth.com), and a tabular COVID-19 "Cockpit" (Brock et al., 2022). Together they are aimed at enabling a variety of use-case scenarios useful to support translational and clinical researchers in hypothesis generation and the development of

### [3] Gathering Evidence of Mechanisms
- Authors: Veli-Pekka Parkkinen, Christian Wallmann, Michael Wilde, B. Clarke, P. Illari et al.
- Year: 2018
- Venue: Unknown venue
- URL: https://www.semanticscholar.org/paper/06480fd932fc88915a4efb4c894a5ae4ed98452d
- DOI: 10.1007/978-3-319-94610-8_5
- Citations: 1
- Summary: Key issues include increased precision concerning the nature of the hypothesis being examined, attention to differences between the study population and the target population of the evidence assessors, and being alert for masking mechanisms, which are other mechanisms which may mask the action of the mechanism being assessed.
- Evidence snippets:
  - Snippet 1 (score: 0.580)
    > General mechanistic claim for efficacy. In formulating the general mechanistic claim for efficacy, the following questions should be addressed:
    > • What is the relevant population?
    > • What is the intervention or exposure level?
    > • What is the outcome and how is it measured? General mechanistic claim for external validity. In determining the general mechanistic claim concerning external validity, the following questions should be addressed:
    > • What is the target population? What is the study population?
    > • What is the intervention or exposure level in the target?
    > • What is the outcome and how is it measured in the target?
    > • What is the intervention or exposure level in the study?
    > • What is the outcome and how is it measured in the study?
    > It may be that existing evidence from clinical studies together with already wellestablished mechanisms is enough to establish the general mechanistic claim. In other cases, the existing evidence fails to establish causality, and it is necessary to identify and evaluate mechanistic studies. To this end, this chapter presents the following five-step strategy for gathering evidence of mechanisms:
    > 1. Identify: Identify a number of specific mechanism hypotheses. 2. Formulate: For each specific mechanism hypothesis, formulate a number of review questions. 3. Search: Use these review questions to search the literature. 4. Refine: Identify the evidence most relevant to the mechanism hypothesis by refining the results of this search. 5. Present. Present the evidence relevant to the mechanism hypothesis. This strategy is intended to help overcome some of the practical difficulties with identifying evidence of mechanisms-difficulties which may prevent appraisers from considering all the relevant evidence. Once this evidence of mechanisms has been identified, it can then be evaluated alongside the existing evidence of correlation from clinical studies, as explained in Chaps. 6 and 7.
    > The overall approach of this chapter is illustrated in Fig. 5.1. The five steps outlined above are explained in detail in the following sections.
  - Snippet 2 (score: 0.551)
    > Although ACE-inhibitors have proved beneficial for hypertension in many study populations, there remains the question of whether they are the optimal treatment in some distinct target population, such as African or Caribbean populations. In this case, it is necessary to determine the status of the following general mechanistic claim: the relevant hypertensive mechanisms in the study populations are sufficiently similar to the mechanisms in African or Caribbean populations. This general mechanistic claim can be evaluated by evaluating a more specific mechanism hypothesis, namely that African and Caribbean populations have a lower renin state. As we shall see in Chap. 6, there is some good mechanistic evidence in favour of this specific mechanism hypothesis, and this undermines the general mechanistic claim. This is why, instead, calcium channel blockers are the recommended antihypertensive treatment in African and Caribbean populations (Clarke et al. 2014).
    > There are two main ways to identify a specific mechanism hypothesis. First, a specific mechanism hypothesis may be proposed on the basis of published studies from the clinical study literature. If a clinical study establishes a correlation between a putative cause and effect, and the suggestion is that this correlation is causal, then the authors of such a study usually identify at least one possible mechanism hypothesis of the following form: It is plausible that mechanism with features F links the putative cause and effect in the study population. The study may also point out possible masking mechanisms (Illari 2011). Given this, the discussion section of a published paper that reports the results of a clinical study is a good place to look in order to locate a specific mechanism hypothesis.
  - Snippet 3 (score: 0.487)
    > The overall approach to gathering evidence of mechanisms of action. Each proposed mechanism of action, or partial description of proposed mechanism of action, is a specific mechanism hypothesis. But note that a specific mechanism hypothesis need not be a complete description of a mechanism.
    > Example: Specific mechanism hypotheses for determining efficacy.
    > Aspirin prevents heart disease via cyclooxygenase (COX) inhibition, and the mechanisms that underlie this prevention are established. However, aspirin also seems to reduce the incidence of some cancers. Here, the mechanisms are much less well understood. As Chan et al. (2011) write: "the mechanism of aspirin's antineoplastic effect is less clear, with substantial evidence supporting both COX-dependent and COX-independent mechanisms. Moreover, data supporting the importance of COX-dependent mechanisms are not entirely consistent concerning the relative importance of the COX-1 and COX-2 isoforms in carcinogenesis". In this quotation, the general mechanistic claim is that aspirin exhibits an antineoplastic effect. There are also a couple of more specific mechanism hypotheses, for example, that this antineoplastic effect is mediated by COX-dependent mechanisms. Evidence relating to these more specific mechanism hypotheses provides a way to determine the status of the general mechanistic claim.
    > External validity. In order to evaluate the general mechanistic claim that there is a mechanism in the target population sufficiently similar to the mechanism responsible for the correlation observed in the study population, specific mechanism hypotheses need to pertain to the mechanism of action. It is important to consider the possibility that the mechanism in the target population may contain further component mechanisms that counteract the mechanism of action in the study population and affect the extent of the correlation between the putative cause and effect. So one needs to ask, are there any masking mechanisms in the target population?
    > Example: Specific mechanism hypotheses for determining external validity.
    > According to NICE guidelines, treatment for hypertension should differ depending on ethnicity (NICE 2011). Although ACE-inhibitors have proved beneficial for hypertension in many study populations, there remains the question of whether they are the optimal treatment in some distinct target population, such as African or Caribbean populations.

### [4] Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study
- Authors: F. D. de Abajo, S. Rodríguez‐Martín, V. Lerma, G. Mejía-Abril, M. Aguilar et al.
- Year: 2020
- Venue: Lancet (London, England)
- URL: https://www.semanticscholar.org/paper/5ea714f2f9622f9030f104a7eb50b0b79b2f106b
- DOI: 10.1016/S0140-6736(20)31030-8
- PMID: 32416785
- PMCID: 7255214
- Citations: 377
- Influential citations: 16
- Summary: RAAS inhibitors do not increase the risk of COVID-19 requiring admission to hospital, including fatal cases and those admitted to intensive care units, and should not be discontinued to prevent a severe case of COVID-19.
- Evidence snippets:
  - Snippet 1 (score: 0.539)
    > Evidence before this study Inhibitors of the renin-angiotensin-aldosterone system (RAAS) have been hypothesised to predispose patients to more severe COVID-19. This hypothesis is based on two facts: these drugs have been reported to upregulate the expression of angiotensinconverting enzyme (ACE) 2, the gateway used by severe acute respiratory syndrome coronavirus 2 to enter cells, and patients with severe COVID-19 have a high prevalence of cardiovascular diseases. Many scientific societies adopted the position of not recommending the discontinuation of treatment. Yet, epidemiological evidence is lacking and the hypothesis has not been confirmed or refuted. We searched PubMed on April 15, 2020, for publications in English since Jan 1, 2020, using the search terms "COVID-19" and "ACE inhibitors OR angiotensin-converting enzyme inhibitors OR angiotensin receptor blockers OR RAAS inhibitors OR RAS inhibitors OR RAAS blockers OR RAS blockers", filtering by "human" and "observational study", and no result was returned.

### [5] Network-based integrative multi-omics approach reveals biosignatures specific to COVID-19 disease phases
- Authors: Francis E. Agamah, Thomas H. A. Ederveen, Michelle Skelton, Darren P. Martin, Emile R. Chimusa et al.
- Year: 2023
- Venue: Frontiers in Molecular Biosciences
- URL: https://www.semanticscholar.org/paper/17f9e0e3ecb026cc63a5d13c4917c27ea0253318
- DOI: 10.3389/fmolb.2024.1393240
- PMID: 39040605
- PMCID: 11260748
- Citations: 4
- Summary: This study identified both biosignatures of different omics types enriched in disease-related pathways and their associated interactions that are either common between or unique to mild, moderate, and severe COVID-19 disease phases.
- Evidence snippets:
  - Snippet 1 (score: 0.523)
    > Having demonstrated that cross-layer interactions could be a distinctive feature, if not a hallmark, of severe COVID-19, it warrants deeper investigation into the potential causal relationships that these cross-layer interactions, have with disease progression: relationships that might illuminate ways to prevent and/or reverse this progression.
    > IL6 is a vital innate immune cytokine in protection against other viral infections such as influenza A virus, which can cause pneumonia (Guirao et al., 2020). An increase in IL6 levels has previously been observed in patients with respiratory dysfunction, implying a possible mechanism of cytokine-mediated lung damage caused by COVID-19 infection (Gou et al., 2020;Guirao et al., 2020). Our hypothesis-driven approach revealed that higher COVID-19 disease severity was associated with an increased number of interactions between IL6 and other multi-omics layers, therefore suggesting that our approach may discriminate between COVID-19 and other respiratory disorders. However, to confirm we will need future studies on the evaluation of network-based multi-omics approaches for COVID-19 compared to other infectious diseases, including those of viral and bacterial nature.
    > Our study suggests a deeper understanding of the underlying biological interactions in different phases of COVID-19 disease. The results (Figures 4,5,along with Table 5; Supplementary Table S3 and Supplementary Material S2) present an extensive analysis of multilayered graphs generated by complementary approaches including data-driven and hypothesis-driven seeds, and shed light on the complex interactions underlying different phases of COVID-19. These findings suggest a nuanced understanding of how various molecular features interact and influence disease severity. However, heterogeneity, different sample sizes, and sensitivity of types of samples used for sequencing across studies might be a potential source of bias. The hypothesis-driven approach offers a reductionist strategy for experimental proof whereas the data-driven approach offers a holistic strategy and hypothesis generation. We recommend considering both data-and hypothesis-driven approaches in studies utilizing multiple source omics datasets. Also, the complexity of disease severity harmonization, identifier mapping, and feature selection might be potential sources of bias in our studies.

### [6] The use of mechanistic reasoning in assessing coronavirus interventions
- Authors: J. Aronson, Daniel Auker-Howlett, Virginia Ghiara, Michael P Kelly, Jon Williamson
- Year: 2020
- Venue: Journal of Evaluation in Clinical Practice
- URL: https://www.semanticscholar.org/paper/8181228edcb8feefeb80c9f97f77d5ac4fe9dae6
- DOI: 10.1111/jep.13438
- PMID: 32666676
- PMCID: 7405225
- Citations: 13
- Summary: It is concluded that coronavirus research is best situated within the EBM+ evaluation framework, a development of EBM that systematically considers mechanistic studies alongside association studies.
- Evidence snippets:
  - Snippet 1 (score: 0.510)
    > along channels M 1 , M 2 , and/or M 3 is mechanistic reasoning. Mechanistic reasoning is particularly pertinent when specific hypotheses about key features of the mechanism complex are established (or ruled out) by mechanistic studies (see Section 3).
    > Given this more nuanced picture of causal assessment, it can be important to explicitly and systematically scrutinize mechanistic studies when assessing causal claims. This need is now often recognized when assessing the effects of environmental exposures 4 but less so when assessing the effects of interventions 5,6 and of infectious diseases. 7 In this paper, we aim to redress the balance by showing that there is a need to assess mechanistic studies explicitly and systematically when interrogating the effects of interventions in infections with coronaviruses. Indeed, this need is particularly urgent in diseases such as SARS, MERS, and COVID-19 (due respectively to SARS-CoV-1, MERS-CoV, and SARS-CoV-2), because outbreaks are rapid, limiting the opportunity to conduct high-quality RCTs. Thus, association studies on their own tend to provide evidence that is too weak to establish causation. When rapid outbreaks are coupled with severe disease, effective interventions need to be identified very quickly. In these circumstances, only by considering mechanistic studies alongside association studies is it possible to build an evidence base that distinguishes those interventions that are effective from those that are ineffective.
    > In the following sections, we provide several examples of the importance of mechanistic evidence to coronavirus research. The assessment of combination therapy for MERS highlights the difficulties that can be encountered when suggesting treatments on the basis of poor mechanistic reasoning (Section 2). That treatment for hypertension is a risk factor for severe disease in the case of SARS-CoV-2 suggests that altering hypertension treatment might alleviate disease, but the mechanisms are complex, and it is essential to consider and evaluate more than one mechanistic hypothesis (Section 3). To successfully limit the spread of an infection, public health interventions need to take account of all relevant social mechanisms, rather than just targeting risk factors. Moreover, interventions shown to be effective in one country cannot be successfully extrapolated to other countries unless the relevant social mechanisms are sufficiently similar,

### [7] The peripheral and core regions of virus-host network of COVID-19
- Authors: Bingbo Wang, Xianan Dong, Jie Hu, Xiujuan Ma, Chao Han et al.
- Year: 2021
- Venue: Briefings in Bioinformatics
- URL: https://www.semanticscholar.org/paper/eab5ec5446a62abe1461e15c8ae2e15e7a267c8c
- DOI: 10.1093/bib/bbab169
- PMID: 33956950
- PMCID: 8136014
- Citations: 7
- Summary: It is found that the virus-host proteins (VHPs) form a significantly connected VHN, among which highly perturbed proteins aggregate into an observable core region and the periphery-core pattern can offer insights into interconnectivity of SARS-CoV-2 VHPs but also facilitate the research on therapeutic drugs.
- Evidence snippets:
  - Snippet 1 (score: 0.508)
    > In this study, we draw upon the latest advances in COVID-19 virus-host research and network medicine methods to identify the VHN and core region of COVID-19, and we find that both VHN and core regions are internally tightly connected topologies in the human interactome. Then, we combine the C3 disease modules of 70 diseases and the core regions of SARS and H1N1 to analyze the disease similarity. We compute their network distance with the VHN or core region of COVID-19 based on their location in human interactome and find several high similarity diseases including immune and neurological diseases and cancers. We identified drug targets based on network proximity and predicted drug outcomes as high as 0.77, suggesting that COVID-19's peripheral and core regions also provide an opportunity for drug repurposing. This result can provide new insights into understanding the disease mechanisms of COVID-19 and guide us in the prevention and treatment of COVID-19.
    > Core region typically consists of genes specific for the underlying disease. Based on the hypothesis that the similar molecular mechanism of diseases lies in their overlapped peripheries, we identify the molecular mechanism of disease causation, new comorbidity and aid rational drug target for COVID-19. In particular, we construct the flower model for COVID-19, SARS and H1N1 and show the details of their overlapped peripheral proteins. Enrichment analysis further proved that overlapped peripheries consistently enrich in Parkinson Disease, Huntington Disease, Alzheimer Disease and Non-Alcoholic Fatty Liver Disease pathways; provide 16 proteins targeted by 9 existing drugs currently undergoing clinical trials and drugs predicted by periphery have a certain effectiveness in the treatment of COVID-19. The periphery and core structure of COVID-19 provides new insights for the analysis of disease relationship and drug prediction.
    > Although Ratnakumar et al. [21] proposed instructive methods for identifying disease core genes, there are variety of definitions including highest differential expression level, strongest effect mutations or interpretable mechanistic links to disease.

### [8] Neuropsychiatric Manifestations of COVID-19 Disease and Post COVID Syndrome: The Role of N-acetylcysteine and Acetyl-L-carnitine
- Authors: Tommaso Barlattani, G. Celenza, Alessandro Cavatassi, Franco Minutillo, Valentina Socci et al.
- Year: 2024
- Venue: Current Neuropharmacology
- URL: https://www.semanticscholar.org/paper/7983b3e1ea4f96a2306dee81711ad8155f23ea80
- DOI: 10.2174/011570159X343115241030094848
- PMID: 39506442
- PMCID: 12163478
- Citations: 12
- Influential citations: 1
- Summary: A pathophysiological model explaining the effectiveness of NAC and ALC in treating COVID-19-related neuropsychiatric symptoms is proposed, with potentially synergistic effects on chronic pain and neuro-astrocyte protection.
- Evidence snippets:
  - Snippet 1 (score: 0.505)
    > Terms and databases were combined using the Boolean search technique to make search more restrictive and detailed. Only studies published in English have been included. The main results were then discussed narratively divided by paragraphs, respectively: SARS-CoV-2 Neuroinvasion in COVID-19: overview of Entry Mechanisms; COVID-19induced Brain Damage and Neuropsychiatric Consequences; Neuropsychiatric Symptoms in Acute COVID-19, Ongoing COVID-19, and PCS; NAC and ALC: overview and mechanism of action; Hypothesis and Rationale of NAC and ALC in neuropsychiatric manifestations of acute COVID-19 disease, ongoing symptomatic COVID-19, PCS".

### [9] A diseasome cluster-based drug repurposing of soluble guanylate cyclase activators from smooth muscle relaxation to direct neuroprotection
- Authors: F. Langhauser, A. I. Casas, V. Dao, E. Guney, Jörg Menche et al.
- Year: 2018
- Venue: NPJ Systems Biology and Applications
- URL: https://www.semanticscholar.org/paper/44d6cd1d0dd2993b9a9f6b17e3f9705fb04892b8
- DOI: 10.1038/s41540-017-0039-7
- PMID: 29423274
- PMCID: 5799370
- Citations: 61
- Influential citations: 2
- Summary: It is shown that, based on this principle, a cardio-pulmonary drug can be surprisingly repurposed for a previously not recognised application as a direct neuroprotectant, and it is found that the cyclic GMP forming soluble guanylate cyclase becomes dysfunctional upon stroke but regains catalytic activity in the presence of specific activator compounds.
- Evidence snippets:
  - Snippet 1 (score: 0.501)
    > Drug discovery and development follows a relatively uniform path from mechanistic hypothesis, preclinical disease models to clinical validation. However, in recent years, a string of major drug developments have failed due to lack of efficacy. 1 One reason for this appears to reside in our current definitions of 'disease', i.e., mostly organ-based or by an apparent phenotype or symptom and not by an underlying mechanisms. However, without a validated pathomechanism no mechanism-based drugs can be developed and, therefore, rather surrogate parameters or risk factors are treated instead. Finding a rational approach towards mechanism-based disease definitions may therefore have a tremendous impact on drug discovery and medicine in general.
    > Using a data-driven approach, disease-disease networks (diseosome) have been constructed in which diseases are linked based on common molecular or regulatory mechanisms, 2 such as shared genetic associations, 2 protein interactions 3,4 or gene-disease interactions. 5 These diseasomes exhibit local clusters of diseases whose molecular relationships are well understood, but also unexpected clusters of surprisingly heterogeneous diseases. 3 Such clustering of disease phenotypes is likely due to underlying hidden common pathomechanisms. Importantly, these common mechanism clusters may provide previously unrecognized molecular definitions of these phenotypes and at the same time targets for mechanism-based drug discovery and repurposing.
    > Here we test the clinical validity of this approach by focusing on one cluster of highly prevalent combinations of vascular, neurological and metabolic disease phenotypes with high unmet medical need. Genetic evidence points to cGMP signaling as being part of its underlying pathomechanism. 5,6 We then inquire in a non-hypothesis-based manner using disease-disease networks based on common genetic origins, common protein interactions between disease genes, shared disease symptoms and disease co-morbidity for possible drug repurposing of cGMP modulators within this cluster.

### [10] The cognitive science of COVID-19: Acceptance, denial, and belief change
- Authors: P. Thagard
- Year: 2021
- Venue: Methods (San Diego, Calif.)
- URL: https://www.semanticscholar.org/paper/76beb1dd87692e36d49120c0e07dfe80b6f8b8d9
- DOI: 10.1016/j.ymeth.2021.03.009
- PMID: 33744395
- PMCID: 8545909
- Citations: 18
- Influential citations: 1
- Summary: Because the spread of pandemics depends heavily on human choices and behaviors, dealing with COVID-19 requires insights from cognitive science which integrates psychology, neuroscience, computer modeling, philosophy, anthropology, and linguistics.
- Evidence snippets:
  - Snippet 1 (score: 0.499)
    > The alternative account of inference to causal hypotheses is the theory of explanatory coherence that has been applied to many cases of medical and scientific reasoning such as the claim that the Zika virus causes birth defects [9][10][11][12][13][14]. This theory is based on the philosophical idea that causal reasoning is inference to the best explanation of the available evidence, but fleshes it out into a computational model using neural networks that do not require probabilities. Instead, causal reasoning is understood as a process of simultaneously satisfying multiple constraints.
    > The main positive constraints for explanatory coherence are that causal hypotheses explain the evidence for them and that these hypotheses can in turn be explained by deeper hypotheses concerning the relevant mechanisms. For example, the hypothesis that wearing masks prevents disease explains various pieces of evidence such as that there is less spread of disease in mask-wearing countries such as China. Moreover, scientists can explain the effectiveness of wearing masks by identifying the underlying mechanism: the virus spreads on droplets through the air and masks block the droplets. Hence the claim that wearing masks prevents disease spread gets coherence both from what it explains and from what explains it.
    > The main negative constraints operating in explanatory coherence concern the alternative causal hypotheses that compete with each other. For example, the hypothesis that wearing masks prevents disease has to compete with the hypothesis that masks do not prevent disease which purports to explain other pieces of evidence such as that medical personnel get sick despite wearing masks. A hypothesis is accepted or rejected based on its overall coherence with all of the evidence and all other hypothesis, where coherence is a matter of satisfying as many constraints as possible. Fig. 1 shows the structure of the explanatory coherence assessment of the mask hypothesis. The hypothesis that wearing masks causes a reduction of spread of COVID-19 gets its explanatory coherence from 4 directions: what it explains, what explains it, analogy with SARS and other infectious diseases, and competition with the claim that masks do not prevent COVID-19 [15][16][17][18][19][20][21][22][23][24][25]

### [11] Malaria, COVID-19 and angiotensin-converting enzyme 2: what does the available population data say?
- Authors: A. De, M. Dash, A. Tiwari, A. Sinha
- Year: 2021
- Venue: Open Biology
- URL: https://www.semanticscholar.org/paper/5f3bcc1a04189b2360efd02fd025fed381d55eb9
- DOI: 10.1098/rsob.210213
- PMID: 34637655
- PMCID: 8510699
- Citations: 2
- Summary: Based on the existing global and Indian data on malaria, COVID-19 and the suggested ACE2 mutation, the association could not be examined robustly, neither accepting nor refuting the suggested hypothesis.
- Evidence snippets:
  - Snippet 1 (score: 0.498)
    > The etiopathogenesis of COVID-19 and its differential geographic spread suggest some populations are apparently ‘less affected’ through many host-related factors that involve angiotensin-converting enzyme 2 (ACE2) protein, which is also the entry receptor for SARS-CoV-2. The role of ACE2 has been well studied in COVID-19 but not in the context of malaria and COVID-19. We have previously suggested how malaria might intersect with COVID-19 through ACE2 mutation and here we evaluate the currently available data that could provide a link between the two diseases. Based on the existing global and Indian data on malaria, COVID-19 and the suggested ACE2 mutation, the association could not be examined robustly, neither accepting nor refuting the suggested hypothesis. We strongly recommend targeted evaluation of this hypothesis through carefully designed robust molecular epidemiological studies.

### [12] Systems Bioinformatics Reveals Possible Relationship between COVID-19 and the Development of Neurological Diseases and Neuropsychiatric Disorders
- Authors: Anna Onisiforou, G. Spyrou
- Year: 2022
- Venue: Viruses
- URL: https://www.semanticscholar.org/paper/6db0f7d994622b5e960d5b8ae7cb402b584d9816
- DOI: 10.3390/v14102270
- PMID: 36298824
- PMCID: 9611753
- Citations: 17
- Summary: The results suggest that there might be an increased risk for the development of NDs after COVID-19 both via autoreactivity and virus–host PPIs.
- Evidence snippets:
  - Snippet 1 (score: 0.484)
    > Moreover, in this study we choose to focus on a specific list of 10 neurological diseases and 3 neuropsychiatric disorders. The diseases/disorders examined in this study were selected based on the hypothesis that diseases/disorders whose development and/or progression has been associated with viral infections have a higher probability to be triggered by a new emerging virus, in this case SARS-CoV-2, than other diseases, as viruses share several common pathogenic mechanisms. However, our selection list is not exhaustive as other neurological diseases or even other types of diseases, particularly autoimmune diseases, which have a strong association with viral infections can also potentially be triggered by COVID-19. Nonetheless, these diseases are beyond the scope of this paper and may be addressed in future works using the presented computational methodology.

### [13] Renin–angiotensin–aldosterone system inhibitors and the risk of mortality in patients with hypertension hospitalised for COVID-19: systematic review and meta-analysis
- Authors: A. Ssentongo, P. Ssentongo, Emily S. Heilbrunn, A. Lekoubou, P. Du et al.
- Year: 2020
- Venue: Open Heart
- URL: https://www.semanticscholar.org/paper/73750af75fcbb0a0bec4280179f3dbbf5fa889b7
- DOI: 10.1136/openhrt-2020-001353
- PMID: 33154144
- PMCID: 7646321
- Citations: 34
- Summary: Patients with hypertension with prior use of RAAS inhibitors were 35% less likely to die from COVID-19 compared with patients with hypertension not taking RAas inhibitors, suggesting a potential protective effect of RAas-inhibitors in CO VID-19 patients with pulmonary hypertension.
- Evidence snippets:
  - Snippet 1 (score: 0.474)
    > studies, this systematic review and meta-analysis incorporated evidence from the most recent studies, and a large sample size.
    > Potential mechanisms RAAS-inhibitors have been found to mitigate the risk of severe lung injury by reducing the activation of the RAAS through the inactivation of angiotensin II 4 and the generation of angiotensin (1-9) 5 and angiotensin (1-7). 39 Angiotensin (1-7) binds to the G protein-coupled receptors Mas to mediate various physiological effects including vasorelaxation, cardioprotection, antioxidation and inhibition of angiotensin II-induced signalling. This is one hypothesised mechanism illustrating how the treatment of chronic conditions with RAAS-inhibitors may be beneficial in COVID-19 patients. Alternatively, it is hypothesised that the biological mechanisms of RAAS inhibitors may predispose COVID-19 patients to severe disease and even mortality. These hypotheses are based on the observation that SARS-CoV-2 binds to the ACE2, which serves as host cell entry receptor. Animal models suggest that ACEis and ARBs increase membrane-bound ACE2 receptors, which then increases the availability of cells for SARS-CoV-2 to bind and cellular entry. 7 This hypothesis has sparked a debate in populations, for many individuals taking RAAS inhibitors have grown concerned that their medications may be predisposing them to developing COVID-19, and later dying from it. 40 Our meta-analysis supports the notion that RAAS inhibitor exposure does not increase COVID-19-related mortality but rather shows a possible beneficial effect. Future studies should continue to explore the association between COVID-19 and the use of RAAS-inhibitors to further ascertain these findings.

### [14] Type I interferon signaling in SARS-CoV-2 associated neurocognitive disorder (SAND): Mapping host-virus interactions to an etiopathogenesis
- Authors: G. Vavougios, G. A. de Erausquin, H. Snyder
- Year: 2022
- Venue: Frontiers in Neurology
- URL: https://www.semanticscholar.org/paper/b12780ce3683c282a128917b0bdbc13fd2798ab6
- DOI: 10.3389/fneur.2022.1063298
- PMID: 36570454
- PMCID: 9771386
- Citations: 8
- Influential citations: 1
- Summary: This manuscript discusses the molecular basis for a SARS-CoV-2-associated neurocognitive disorder (SAND) focusing on specific genes and pathways with potential mechanistic implications, several of which have been predicted by Vavougios and their research group.
- Evidence snippets:
  - Snippet 1 (score: 0.473)
    > Epidemiological, clinical, and radiological studies have provided insights into the phenomenology and biological basis of cognitive impairment in COVID-19 survivors. Furthermore, its association with biomarkers associated with neuroinflammation and neurodegeneration supports the notion that it is a distinct aspect of LongCOVID syndrome with specific underlying biology. Accounting for the latter, translational studies on SARS-CoV-2's interactions with its hosts have provided evidence on type I interferon dysregulation, which is seen in neuroinflammatory and neurodegenerative diseases. To date, studies attempting to describe this overlap have only described common mechanisms. In this manuscript, we attempt to propose a mechanistic model based on the host-virus interaction hypothesis. We discuss the molecular basis for a SARS-CoV-2-associated neurocognitive disorder (SAND) focusing on specific genes and pathways with potential mechanistic implications, several of which have been predicted by Vavougios and their research group. Furthermore, our hypothesis links translational evidence on interferon-responsive gene perturbations introduced by SARS-CoV-2 and known dysregulated pathways in dementia. Discussion emphasizes the crosstalk between central and peripheral immunity via danger-associated molecular patterns in inducing SAND's emergence in the absence of neuroinfection. Finally, we outline approaches to identifying targets that are both testable and druggable, and could serve in the design of future clinical and translational studies.

### [15] Utility of compartmental models to test the competing hypotheses of pathogen evolution and human intervention
- Authors: Barsha Saha, Majid Bani-Yaghoub, C. Podder
- Year: 2026
- Venue: Frontiers in Public Health
- URL: https://www.semanticscholar.org/paper/749f3bc337708c7462f520ae5f06ceb914a49149
- DOI: 10.3389/fpubh.2025.1702428
- PMID: 41626397
- PMCID: 12853639
- Citations: 1
- Summary: A new model-based hypothesis testing (MBHT) approach, which uses compartmental models to evaluate the hypotheses in epidemiology and reveals that model-based hypothesis testing offers a powerful yet underutilized approach to uncovering drivers of viral mutation and gaining deeper insights into pathogen evolution during outbreaks.
- Evidence snippets:
  - Snippet 1 (score: 0.468)
    > Model-Based Hypothesis Testing (MBHT) is a framework that enables researchers to evaluate competing mechanistic hypotheses by integrating compartmental models with relevant data. In many settings, there is insufficient direct evidence to distinguish among hypotheses at the level of individual parameters or mechanisms. Unlike traditional hypothesis testing, which typically relies on a test statistic derived from observed data, MBHT leverages the output of a validated dynamical model that captures the underlying ecological, evolutionary, or epidemiological processes (37,38). For example, even when direct measurements of disease transmission rates or virulence are unavailable, their distributions can be inferred by fitting a compartmental model to morbidity and mortality data. These inferred parameter distributions can then be used to quantify the relative support for alternative hypotheses. In this way, MBHT enhances the specificity and interpretability of inference by comparing hypotheses through model-based simulations rather than relying solely on empirical contrasts.
    > The MBHT approach differs fundamentally from classical hypothesis testing by offering a mechanistic, model-driven framework tailored to nonlinear, time-dependent systems. Conventional statistical methods typically compare outcomes between control and treatment groups, assuming that the relevant mechanisms can be probed directly from data. In contrast, MBHT relies on model analysis and simulation to identify the best-supported hypothesis, especially when key mechanisms are only indirectly observed (39). Algorithms such as Approximate Bayesian Computation, Markov Chain Monte Carlo, and machinelearning-based emulators can be used to align model output with observed data and to assess the robustness of conclusions. This makes MBHT particularly well suited for dynamic systems such as pathogen evolution, where feedbacks between transmission, immunity, and intervention strategies create complex adaptive and co-evolutionary dynamics that may not be adequately captured by standard statistical tests. Figure 1 summarizes the typical workflow for applying MBHT to ecological and evolutionary systems or other complex dynamical settings. First, competing hypotheses are formulated on the basis of a comprehensive literature review and supplemented with data from relevant repositories. To test these hypotheses, a compartmental disease model is constructed, analyzed using standard mathematical tools, and simulated by sampling parameter values from specified prior ranges.

### [16] Statistical Hypothesis Testing versus Machine Learning Binary Classification: Distinctions and Guidelines
- Authors: J. Li, Xin Tong
- Year: 2020
- Venue: Patterns
- URL: https://www.semanticscholar.org/paper/60ef10665e62aafb9c0990148c79aa619b55eede
- DOI: 10.1016/j.patter.2020.100115
- PMID: 33073257
- PMCID: 7546185
- Citations: 42
- Influential citations: 1
- Summary: Key distinctions between these two strategies in hypothesis testing and binary classification are summarized in three aspects and five practical guidelines for data analysts to choose the appropriate strategy for specific analysis needs are listed.
- Evidence snippets:
  - Snippet 1 (score: 0.468)
    > Hypothesis testing and binary classification are rooted in two different cultures: inference and prediction, each of which has been extensively studied in statistics and machine learning respectively in the historical development of data sciences [9].Briefly, an inferential task aims to infer an unknown truth from observed data, and hypothesis testing is a specific framework whose inferential target is a binary truth, i.e., an answer to a yes/no question.For example, deciding whether a gene is an effective COVID-19 biomarker in the blood is an inferential question, whose answer is unobservable.In contrast, a prediction task aims to predict an unobserved property of an instance, such as a patient or an object, based on the available features of this instance.Such prediction relies on building a trustworthy relationship, i.e., a prediction rule, from the input features to the target property, which must be based on human knowledge (throughout the human history) and/or established from data (after computing devices were developed).Binary classification is a special type of prediction whose target property is binary, and COVID-19 diagnosis is an example.In screening patients for COVID-19 exams, medical doctors make binary decisions based on patients' symptoms (input features), and their decision rules are learned from previous patients' diagnostic data and medical literature.
    > Hypothesis testing is built upon the concept of statistical significance, which intuitively means that the data we observe present strong evidence against a presumed null hypothesis, the default.In the example of testing whether a gene is a COVID-19 biomarker in blood, the null hypothesis is that this gene does not exhibit differential expression in the blood of uninfected individuals and COVID-19 patients.This formulation reflects a conservative attitude: we do not want to call the gene a biomarker unless its expression difference is large enough between the healthy and diseased patients we measured.Statistical hypothesis testing provides a formal framework for deciding a threshold on the expression difference so that the gene can be identified as a biomarker with the desired confidence.A crucial fact about hypothesis testing is that the null and alternative hypotheses pertain to a property of an unseen population.As a result, we cannot know whether the null hypothesis holds or not.

### [17] Antibody Consumption-Driven Dynamic Competition: A Systems Hypothesis for the Transition from Acute Immune Response to Post-Infection Sequelae
- Authors: Shi Qiru
- Year: 2025
- Venue: Unknown venue
- URL: https://www.semanticscholar.org/paper/3e1f1c1f620a30dc53bafafb41597a1d513b84e8
- Summary: The proposed three-phase consumption-driven dynamic competition model provides a unified and dynamic explanatory framework for understanding the significant individual variability and dynamic evolution of post-infection immune outcomes (including the emergence and self-limitation of acute symptoms, the formation and persistence of chronic sequelae, and symptom fluctuations or resolution).
- Evidence snippets:
  - Snippet 1 (score: 0.467)
    > As previously stated (Sec. 4), the core challenge of this hypothesis is its testability. Even within the idealized animal model designed in Section 4.1, there remain significant technical difficulties in precisely and dynamically measuring local antibody consumption rates and their immediate impact on B cell production. This makes it complex to establish a direct causal link between systemic antibody concentration changes and local competitive dynamics, which is a major obstacle for current verification efforts. Major limitations include: the highly speculative nature of the core consumption sensing/transduction mechanism; simplification of complex immune interactions (e.g., other T cell subsets, innate immunity, microenvironment, immunometabolism); the need to test the universality of the model across different pathogens and host backgrounds; and the risk of a single-perspective view on the multifactorial etiology of sequelae. These challenges and limitations collectively point towards directions for future exploration through theoretical refinement and experimental/technological innovation. 5.4 Near-term Feasible Validation Paths and Prospects Given the technical bottlenecks in direct validation, near-term research should focus on more feasible paths, gradually accumulating indirect evidence and seeking proof-of-concept for key points to support the assessment of this hypothesis. Accumulating Indirect Correlative Evidence: Mechanistic Reinterpretation of Existing Therapies: This hypothesis offers a new explanatory framework for certain therapies effective against sequelae but with unclear mechanisms. These treatments may work by introducing a new, highly competitive immune response that reshapes the competitive landscape, thereby suppressing the autoreactive clones that sustain the sequelae. Based on this, hypothesis-driven optimization strategies can be proposed, with comparative clinical outcomes providing evidence. Systematic Observation of "Infection-Induced Remission of Chronic Diseases": A highly compelling yet often overlooked source of evidence is the observation that some patients experience significant remission, or even resolution, of pre-existing chronic conditions (such as certain autoimmune diseases or allergies) following a strong acute infection. This phenomenon is likely severely underreported due to reporting bias. From our hypothesis's perspective, this is a perfect manifestation of a new, potent immune response successfully "out-competing" the original pathological clones through dynamic competition.

## Notes

- This provider combines `search_papers_by_relevance` with `snippet_search`.
- No synthesis or second-stage model call is performed.
